LEADERSHIP

Nancy Shulman, M.D., has over 20 years of clinical development experience. Prior to Mirum, she worked at Roche, Genentech, AbbVie, Ambys Medicines, and, most recently, at Bluejay Therapeutics, where she was the chief medical officer. She brings broad clinical development experience ranging from first-in-human and translational studies through Phase 4 studies, including extensive experience in the virology/hepatology disease area, and also in immunology and oncology. She has been a part of multiple INDs and was a key leader on the approvals of the HCV antivirals Viekira Pak®, Viekirax® and Mavyret®.

Prior to joining industry, Nancy was an NIH-funded clinical/translational HIV researcher at Stanford University and was on the faculty in the Division of Infectious Diseases. She holds a BA in Biochemistry with a minor in Chinese from the University of Texas at Austin and an MD from the University of Kansas. She completed her residency in internal medicine and pediatrics at the University of Chicago and her infectious disease fellowship at Stanford.